S. Higashi

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Jeff Trent, T. Dorff, S. Highlander, 2022, Nature Medicine.

Comparison of clinical severity, genotype and toxin gene expression of binary toxin-producing Clostridioides difficile clinical isolates in Japan

Asami Matsumoto, Motomichi Takahashi, K. Oka, 2022, Access microbiology.

Clostridium butyricum Modulates the Microbiome to Protect Intestinal Barrier Function in Mice with Antibiotic-Induced Dysbiosis

K. Iwasaki, Susumu Tomono, Asami Matsumoto, 2019, iScience.

Characterization of Reproductive Microbiota of Primiparous Cows During Early Postpartum Periods in the Presence and Absence of Endometritis

S. Kamiya, Motomichi Takahashi, K. Oka, 2021, Frontiers in Veterinary Science.

The impact of probiotic Clostridium butyricum MIYAIRI 588 on murine gut metabolic alterations.

Asami Matsumoto, Takeshi Mori, Motomichi Takahashi, 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Analysis of the colonic mucosa associated microbiota (MAM) using brushing samples during colonic endoscopic procedures.

H. Matsumoto, S. Kamiya, A. Shiotani, 2019, Journal of clinical biochemistry and nutrition.

Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation.

K. Iwasaki, Akinobu Ota, Motomichi Takahashi, 2022, Cell reports.

Clostridium butyricum enhances colonization resistance against Clostridioides difficile by metabolic and immune modulation

K. Iwasaki, Motomichi Takahashi, K. Oka, 2021, Scientific Reports.

Genomic analysis of Shiga toxin-producing Escherichia coli from patients and asymptomatic food handlers in Japan

T. Aoyagi, K. Tokuda, M. Kaku, 2019, PloS one.

Lantibiotics Produced by Oral Inhabitants as a Trigger for Dysbiosis of Human Intestinal Microbiota

H. Yonezawa, S. Kamiya, T. Osaki, 2021, International Journal of Molecular Sciences.